{"transactions":[{"id":700045,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-01T00:00:16.000Z","date":"2026-07-31","kind":"gift","planned":false,"acquired":false,"shares":123840,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":264742,"source":{"system":"sec-edgar","filing":"0001864158-26-000006","document":"form4-07312026_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000006/form4-07312026_080701.xml","form_type":"4"}},{"id":711234,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-11T00:00:05.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":697550,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001864158-26-000004","document":"form4-07102026_080702.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000004/form4-07102026_080702.xml","form_type":"4"}},{"id":711233,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-11T00:00:05.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":true,"shares":7000,"price":4.21,"value":29470.0,"ownership":{"direct":true},"balance_after":388582,"source":{"system":"sec-edgar","filing":"0001864158-26-000004","document":"form4-07102026_080702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000004/form4-07102026_080702.xml","form_type":"4"}},{"id":740083,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-13T00:30:48.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to Dr. Simson's continuous service on each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001231919-26-000631","document":"form4-06132026_120640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000123191926000631/form4-06132026_120640.xml","form_type":"4"}},{"id":740082,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:30:48.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Dr. Jake Simson's continuous service on such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001231919-26-000631","document":"form4-06132026_120640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000123191926000631/form4-06132026_120640.xml","form_type":"4"}},{"id":740132,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:15.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001863094-26-000002","document":"form4-06122026_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000186309426000002/form4-06122026_080611.xml","form_type":"4"}},{"id":740131,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:15.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001863094-26-000002","document":"form4-06122026_080611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000186309426000002/form4-06122026_080611.xml","form_type":"4"}},{"id":740081,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38792,"kind":"person","name":"Kung Winston","position":1,"cik":"0001666963","reported_name":"Kung Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:13.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001666963-26-000003","document":"form4-06122026_080609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000166696326000003/form4-06122026_080609.xml","form_type":"4"}},{"id":740080,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38792,"kind":"person","name":"Kung Winston","position":1,"cik":"0001666963","reported_name":"Kung Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:13.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001666963-26-000003","document":"form4-06122026_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000166696326000003/form4-06122026_080609.xml","form_type":"4"}},{"id":740079,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":30678,"kind":"person","name":"Hernday Natasha","position":1,"cik":"0001780547","reported_name":"Hernday Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001780547-26-000004","document":"form4-06122026_080607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000178054726000004/form4-06122026_080607.xml","form_type":"4"}},{"id":740078,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":30678,"kind":"person","name":"Hernday Natasha","position":1,"cik":"0001780547","reported_name":"Hernday Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":15481,"source":{"system":"sec-edgar","filing":"0001780547-26-000004","document":"form4-06122026_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000178054726000004/form4-06122026_080607.xml","form_type":"4"}},{"id":740077,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":36738,"kind":"person","name":"DOBMEIER ERIC","position":1,"cik":"0001202785","reported_name":"DOBMEIER ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:10.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001202785-26-000002","document":"form4-06122026_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120278526000002/form4-06122026_080605.xml","form_type":"4"}},{"id":740076,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":36738,"kind":"person","name":"DOBMEIER ERIC","position":1,"cik":"0001202785","reported_name":"DOBMEIER ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:10.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":15481,"source":{"system":"sec-edgar","filing":"0001202785-26-000002","document":"form4-06122026_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120278526000002/form4-06122026_080605.xml","form_type":"4"}},{"id":740075,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38791,"kind":"person","name":"CAPPS VICKIE L","position":1,"cik":"0001248190","reported_name":"CAPPS VICKIE L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:09.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001248190-26-000002","document":"form4-06122026_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000124819026000002/form4-06122026_080604.xml","form_type":"4"}},{"id":740074,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38791,"kind":"person","name":"CAPPS VICKIE L","position":1,"cik":"0001248190","reported_name":"CAPPS VICKIE L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:09.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":79598,"source":{"system":"sec-edgar","filing":"0001248190-26-000002","document":"form4-06122026_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000124819026000002/form4-06122026_080604.xml","form_type":"4"}},{"id":740073,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38790,"kind":"person","name":"Barrett Ronald W","position":1,"cik":"0001326330","reported_name":"Barrett Ronald W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:06.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001326330-26-000002","document":"form4-06122026_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000132633026000002/form4-06122026_080601.xml","form_type":"4"}},{"id":740072,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38790,"kind":"person","name":"Barrett Ronald W","position":1,"cik":"0001326330","reported_name":"Barrett Ronald W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:06.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001326330-26-000002","document":"form4-06122026_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000132633026000002/form4-06122026_080601.xml","form_type":"4"}},{"id":749922,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":41429,"kind":"person","name":"Doyle Janeen Noel","position":1,"cik":"0002069239","reported_name":"Doyle Janeen Noel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. & Bus. Dev. Ofcr"}}],"security":"Common Stock","published_at":"2026-06-05T00:00:06.000Z","date":"2026-06-02","kind":"sale","planned":false,"acquired":false,"shares":4059,"price":14.029,"value":56943.711,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":75941,"source":{"system":"sec-edgar","filing":"0002069239-26-000005","document":"form4-06042026_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2069239/000206923926000005/form4-06042026_080601.xml","form_type":"4"}},{"id":781128,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":47724,"kind":"person","name":"Dobek Maria","position":1,"cik":"0002032671","reported_name":"Dobek Maria","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Accounting"}}],"security":"Common Stock","published_at":"2026-05-14T00:00:09.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":2038,"price":14.17,"value":28878.46,"ownership":{"direct":true},"balance_after":32270,"source":{"system":"sec-edgar","filing":"0002032671-26-000004","document":"form4-05132026_080505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032671/000203267126000004/form4-05132026_080505.xml","form_type":"4"}},{"id":919533,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":67758,"kind":"person","name":"Go William","position":1,"cik":"0002108554","reported_name":"Go William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T01:01:40.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":154000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on February 26, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":154000,"derivative":{"exercise_price":13.99,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":154000},"source":{"system":"sec-edgar","filing":"0002108554-26-000004","document":"form4-02052026_010237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000210855426000004/form4-02052026_010237.xml","form_type":"4"}},{"id":919532,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":67758,"kind":"person","name":"Go William","position":1,"cik":"0002108554","reported_name":"Go William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:01:40.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on February 1, 2027."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0002108554-26-000004","document":"form4-02052026_010237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000210855426000004/form4-02052026_010237.xml","form_type":"4"}},{"id":955315,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:17.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":1879,"price":13.73,"value":25798.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."}],"balance_after":83095,"source":{"system":"sec-edgar","filing":"0001864159-26-000002","document":"form4-01022026_090112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415926000002/form4-01022026_090112.xml","form_type":"4"}},{"id":955314,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-03T02:00:14.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":338100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":338100,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":338100},"source":{"system":"sec-edgar","filing":"0001864158-26-000002","document":"form4-01022026_090108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000002/form4-01022026_090108.xml","form_type":"4"}},{"id":955313,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:14.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":96600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":381582,"source":{"system":"sec-edgar","filing":"0001864158-26-000002","document":"form4-01022026_090108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000002/form4-01022026_090108.xml","form_type":"4"}},{"id":955312,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:14.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":8072,"price":13.73,"value":110828.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."}],"balance_after":284982,"source":{"system":"sec-edgar","filing":"0001864158-26-000002","document":"form4-01022026_090108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000186415826000002/form4-01022026_090108.xml","form_type":"4"}},{"id":955279,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70598,"kind":"person","name":"Winter Charles M.","position":1,"cik":"0001960264","reported_name":"Winter Charles M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-03T02:00:12.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":100100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":100100,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":100100},"source":{"system":"sec-edgar","filing":"0001960264-26-000002","document":"form4-01022026_090107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000196026426000002/form4-01022026_090107.xml","form_type":"4"}},{"id":955278,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70598,"kind":"person","name":"Winter Charles M.","position":1,"cik":"0001960264","reported_name":"Winter Charles M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:12.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":28600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":106321,"source":{"system":"sec-edgar","filing":"0001960264-26-000002","document":"form4-01022026_090107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000196026426000002/form4-01022026_090107.xml","form_type":"4"}},{"id":955277,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70598,"kind":"person","name":"Winter Charles M.","position":1,"cik":"0001960264","reported_name":"Winter Charles M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:12.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":2401,"price":13.73,"value":32965.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,834 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025."}],"balance_after":77721,"source":{"system":"sec-edgar","filing":"0001960264-26-000002","document":"form4-01022026_090107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000196026426000002/form4-01022026_090107.xml","form_type":"4"}},{"id":955435,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":41429,"kind":"person","name":"Doyle Janeen Noel","position":1,"cik":"0002069239","reported_name":"Doyle Janeen Noel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. & Bus. Dev. Ofcr"}}],"security":"Stock option (right to buy)","published_at":"2026-01-03T02:00:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":126000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":126000,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0002069239-26-000002","document":"form4-01022026_090103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2069239/000206923926000002/form4-01022026_090103.xml","form_type":"4"}},{"id":955434,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":41429,"kind":"person","name":"Doyle Janeen Noel","position":1,"cik":"0002069239","reported_name":"Doyle Janeen Noel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. & Bus. Dev. Ofcr"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0002069239-26-000002","document":"form4-01022026_090103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2069239/000206923926000002/form4-01022026_090103.xml","form_type":"4"}},{"id":955397,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":47724,"kind":"person","name":"Dobek Maria","position":1,"cik":"0002032671","reported_name":"Dobek Maria","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Accounting"}}],"security":"Stock option (right to buy)","published_at":"2026-01-03T02:00:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":42600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":42600,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":42600},"source":{"system":"sec-edgar","filing":"0002032671-26-000002","document":"form4-01022026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2032671/000203267126000002/form4-01022026_090101.xml","form_type":"4"}},{"id":955396,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":47724,"kind":"person","name":"Dobek Maria","position":1,"cik":"0002032671","reported_name":"Dobek Maria","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Accounting"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":18935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":34308,"source":{"system":"sec-edgar","filing":"0002032671-26-000002","document":"form4-01022026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2032671/000203267126000002/form4-01022026_090101.xml","form_type":"4"}},{"id":955395,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":47724,"kind":"person","name":"Dobek Maria","position":1,"cik":"0002032671","reported_name":"Dobek Maria","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Accounting"}}],"security":"Common Stock","published_at":"2026-01-03T02:00:07.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":1462,"price":13.73,"value":20073.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,834 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025."}],"balance_after":15373,"source":{"system":"sec-edgar","filing":"0002032671-26-000002","document":"form4-01022026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032671/000203267126000002/form4-01022026_090101.xml","form_type":"4"}},{"id":955356,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-02T21:00:15.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":109900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":109900,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":109900},"source":{"system":"sec-edgar","filing":"0002005618-26-000002","document":"form4-01022026_090110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000200561826000002/form4-01022026_090110.xml","form_type":"4"}},{"id":955355,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:00:15.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":31400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":155825,"source":{"system":"sec-edgar","filing":"0002005618-26-000002","document":"form4-01022026_090110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000200561826000002/form4-01022026_090110.xml","form_type":"4"}},{"id":955354,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:00:15.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":2505,"price":13.73,"value":34393.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the \"Plan\") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan.  In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024."}],"balance_after":124425,"source":{"system":"sec-edgar","filing":"0002005618-26-000002","document":"form4-01022026_090110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000200561826000002/form4-01022026_090110.xml","form_type":"4"}},{"id":955411,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70619,"kind":"person","name":"McIver Zachariah","position":1,"cik":"0002050056","reported_name":"McIver Zachariah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-02T21:00:10.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":101500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":101500,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":101500},"source":{"system":"sec-edgar","filing":"0002050056-26-000002","document":"form4-01022026_090105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050056/000205005626000002/form4-01022026_090105.xml","form_type":"4"}},{"id":955410,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70619,"kind":"person","name":"McIver Zachariah","position":1,"cik":"0002050056","reported_name":"McIver Zachariah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:00:10.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":52286,"source":{"system":"sec-edgar","filing":"0002050056-26-000002","document":"form4-01022026_090105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050056/000205005626000002/form4-01022026_090105.xml","form_type":"4"}},{"id":955409,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70619,"kind":"person","name":"McIver Zachariah","position":1,"cik":"0002050056","reported_name":"McIver Zachariah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:00:10.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":2714,"price":13.73,"value":37263.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."}],"balance_after":23286,"source":{"system":"sec-edgar","filing":"0002050056-26-000002","document":"form4-01022026_090105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050056/000205005626000002/form4-01022026_090105.xml","form_type":"4"}},{"id":981745,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-04T01:00:11.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":114768,"derivative":{"exercise_price":10.59,"expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001864159-25-000006","document":"form4-12032025_081207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000006/form4-12032025_081207.xml","form_type":"4"}},{"id":981744,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-12-04T01:00:11.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":633,"price":33.5247,"value":21221.1351,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $33.5247 and the range of prices were between $33.28 and $33.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":84974,"source":{"system":"sec-edgar","filing":"0001864159-25-000006","document":"form4-12032025_081207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000006/form4-12032025_081207.xml","form_type":"4"}},{"id":981743,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-12-04T01:00:11.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":2700,"price":32.8548,"value":88707.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $32.8548 and the range of prices were between $32.27 and $33.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":85607,"source":{"system":"sec-edgar","filing":"0001864159-25-000006","document":"form4-12032025_081207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000006/form4-12032025_081207.xml","form_type":"4"}},{"id":981742,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-12-04T01:00:11.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":true,"shares":3333,"price":10.59,"value":35296.47,"ownership":{"direct":true},"balance_after":88307,"source":{"system":"sec-edgar","filing":"0001864159-25-000006","document":"form4-12032025_081207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000006/form4-12032025_081207.xml","form_type":"4"}},{"id":998981,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-15T01:00:16.000Z","date":"2025-11-14","kind":"exercise","planned":true,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":118101,"derivative":{"exercise_price":10.59,"expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001864159-25-000005","document":"form4-11142025_081103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000005/form4-11142025_081103.xml","form_type":"4"}},{"id":998980,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-15T01:00:16.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":3333,"price":30,"value":99990.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."}],"balance_after":84974,"source":{"system":"sec-edgar","filing":"0001864159-25-000005","document":"form4-11142025_081103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000005/form4-11142025_081103.xml","form_type":"4"}},{"id":998979,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-15T01:00:16.000Z","date":"2025-11-14","kind":"exercise","planned":true,"acquired":true,"shares":3333,"price":10.59,"value":35296.47,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the \"Plan\") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025."}],"balance_after":88307,"source":{"system":"sec-edgar","filing":"0001864159-25-000005","document":"form4-11142025_081103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000005/form4-11142025_081103.xml","form_type":"4"}},{"id":1011431,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T00:00:05.000Z","date":"2025-10-28","kind":"exercise","planned":true,"acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":121434,"derivative":{"exercise_price":10.59,"expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001864159-25-000003","document":"form4-10302025_081001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000003/form4-10302025_081001.xml","form_type":"4"}},{"id":1011430,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T00:00:05.000Z","date":"2025-10-28","kind":"exercise","planned":true,"acquired":false,"shares":9999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":77333,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":9999},"source":{"system":"sec-edgar","filing":"0001864159-25-000003","document":"form4-10302025_081001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000003/form4-10302025_081001.xml","form_type":"4"}},{"id":1011429,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-10-31T00:00:05.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":16665,"price":30.0622,"value":500986.563,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":82139,"source":{"system":"sec-edgar","filing":"0001864159-25-000003","document":"form4-10302025_081001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000003/form4-10302025_081001.xml","form_type":"4"}},{"id":1011428,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-10-31T00:00:05.000Z","date":"2025-10-28","kind":"exercise","planned":true,"acquired":true,"shares":6666,"price":10.59,"value":70592.94,"ownership":{"direct":true},"balance_after":98804,"source":{"system":"sec-edgar","filing":"0001864159-25-000003","document":"form4-10302025_081001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000003/form4-10302025_081001.xml","form_type":"4"}},{"id":1011427,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-10-31T00:00:05.000Z","date":"2025-10-28","kind":"exercise","planned":true,"acquired":true,"shares":9999,"price":4.21,"value":42095.79,"ownership":{"direct":true},"balance_after":92138,"source":{"system":"sec-edgar","filing":"0001864159-25-000003","document":"form4-10302025_081001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000186415925000003/form4-10302025_081001.xml","form_type":"4"}},{"id":1111882,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T23:33:08.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to Dr. Simson's continuous service on each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and RSU and underlying common stock."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017318","document":"form4-06132025_110604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017318/form4-06132025_110604.xml","form_type":"4"}},{"id":1111881,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:33:08.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Dr. Jake Simson's continuous service on such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and RSU and underlying common stock."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001415889-25-017318","document":"form4-06132025_110604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017318/form4-06132025_110604.xml","form_type":"4"}},{"id":1111880,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38790,"kind":"person","name":"Barrett Ronald W","position":1,"cik":"0001326330","reported_name":"Barrett Ronald W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:20.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017317","document":"form4-06132025_070616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017317/form4-06132025_070616.xml","form_type":"4"}},{"id":1111879,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38790,"kind":"person","name":"Barrett Ronald W","position":1,"cik":"0001326330","reported_name":"Barrett Ronald W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:20.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001415889-25-017317","document":"form4-06132025_070616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017317/form4-06132025_070616.xml","form_type":"4"}},{"id":1111878,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38791,"kind":"person","name":"CAPPS VICKIE L","position":1,"cik":"0001248190","reported_name":"CAPPS VICKIE L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017316","document":"form4-06132025_070614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017316/form4-06132025_070614.xml","form_type":"4"}},{"id":1111877,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38791,"kind":"person","name":"CAPPS VICKIE L","position":1,"cik":"0001248190","reported_name":"CAPPS VICKIE L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":74098,"source":{"system":"sec-edgar","filing":"0001415889-25-017316","document":"form4-06132025_070614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017316/form4-06132025_070614.xml","form_type":"4"}},{"id":1111876,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":36738,"kind":"person","name":"DOBMEIER ERIC","position":1,"cik":"0001202785","reported_name":"DOBMEIER ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017315","document":"form4-06132025_070611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017315/form4-06132025_070611.xml","form_type":"4"}},{"id":1111875,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":36738,"kind":"person","name":"DOBMEIER ERIC","position":1,"cik":"0001202785","reported_name":"DOBMEIER ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":9981,"source":{"system":"sec-edgar","filing":"0001415889-25-017315","document":"form4-06132025_070611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017315/form4-06132025_070611.xml","form_type":"4"}},{"id":1111874,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":25886,"kind":"person","name":"GUJRATHI SHEILA","position":1,"cik":"0001575202","reported_name":"Gujrathi Sheila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:17.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017314","document":"form4-06132025_070609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017314/form4-06132025_070609.xml","form_type":"4"}},{"id":1111873,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":25886,"kind":"person","name":"GUJRATHI SHEILA","position":1,"cik":"0001575202","reported_name":"Gujrathi Sheila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:17.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":118889,"source":{"system":"sec-edgar","filing":"0001415889-25-017314","document":"form4-06132025_070609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017314/form4-06132025_070609.xml","form_type":"4"}},{"id":1111872,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":30678,"kind":"person","name":"Hernday Natasha","position":1,"cik":"0001780547","reported_name":"Hernday Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017313","document":"form4-06132025_070608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017313/form4-06132025_070608.xml","form_type":"4"}},{"id":1111871,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":30678,"kind":"person","name":"Hernday Natasha","position":1,"cik":"0001780547","reported_name":"Hernday Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":8731,"source":{"system":"sec-edgar","filing":"0001415889-25-017313","document":"form4-06132025_070608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017313/form4-06132025_070608.xml","form_type":"4"}},{"id":1111868,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":78516,"kind":"person","name":"McNulty Alana B.","position":1,"cik":"0001606086","reported_name":"McNulty Alana B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:14.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017312","document":"form4-06132025_070605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017312/form4-06132025_070605.xml","form_type":"4"}},{"id":1111867,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":78516,"kind":"person","name":"McNulty Alana B.","position":1,"cik":"0001606086","reported_name":"McNulty Alana B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:14.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001415889-25-017312","document":"form4-06132025_070605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017312/form4-06132025_070605.xml","form_type":"4"}},{"id":1111950,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:11.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017311","document":"form4-06132025_070603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000141588925017311/form4-06132025_070603.xml","form_type":"4"}},{"id":1111949,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:11.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001415889-25-017311","document":"form4-06132025_070603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000141588925017311/form4-06132025_070603.xml","form_type":"4"}},{"id":1111870,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38792,"kind":"person","name":"Kung Winston","position":1,"cik":"0001666963","reported_name":"Kung Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:06.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017310","document":"form4-06132025_070601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017310/form4-06132025_070601.xml","form_type":"4"}},{"id":1111869,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":38792,"kind":"person","name":"Kung Winston","position":1,"cik":"0001666963","reported_name":"Kung Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:06.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001415889-25-017310","document":"form4-06132025_070601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925017310/form4-06132025_070601.xml","form_type":"4"}},{"id":1123280,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":41429,"kind":"person","name":"Doyle Janeen Noel","position":1,"cik":"0002069239","reported_name":"Doyle Janeen Noel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. & Bus. Dev. Ofcr"}}],"security":"Stock option (right to buy)","published_at":"2025-06-05T00:00:20.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":154000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on May 14, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":154000,"derivative":{"exercise_price":25.01,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":154000},"source":{"system":"sec-edgar","filing":"0001415889-25-015684","document":"form4-06042025_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2069239/000141588925015684/form4-06042025_080616.xml","form_type":"4"}},{"id":1123279,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":41429,"kind":"person","name":"Doyle Janeen Noel","position":1,"cik":"0002069239","reported_name":"Doyle Janeen Noel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. & Bus. Dev. Ofcr"}}],"security":"Common Stock","published_at":"2025-06-05T00:00:20.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on June 1, 2026."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0001415889-25-015684","document":"form4-06042025_080616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2069239/000141588925015684/form4-06042025_080616.xml","form_type":"4"}},{"id":1161294,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-03T00:00:06.000Z","date":"2025-05-01","kind":"exercise","planned":true,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":87332,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001415889-25-011874","document":"form4-05022025_080503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011874/form4-05022025_080503.xml","form_type":"4"}},{"id":1161293,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-05-03T00:00:06.000Z","date":"2025-05-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":32.6034,"value":13041.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $32.6034 and the range of prices were between $32.52 and $33.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":82139,"source":{"system":"sec-edgar","filing":"0001415889-25-011874","document":"form4-05022025_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011874/form4-05022025_080503.xml","form_type":"4"}},{"id":1161292,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-05-03T00:00:06.000Z","date":"2025-05-01","kind":"sale","planned":true,"acquired":false,"shares":2933,"price":31.9479,"value":93703.1907,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $31.9479 and the range of prices were between $31.44 and $32.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":82539,"source":{"system":"sec-edgar","filing":"0001415889-25-011874","document":"form4-05022025_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011874/form4-05022025_080503.xml","form_type":"4"}},{"id":1161291,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-05-03T00:00:06.000Z","date":"2025-05-01","kind":"exercise","planned":true,"acquired":true,"shares":3333,"price":4.21,"value":14031.93,"ownership":{"direct":true},"balance_after":85472,"source":{"system":"sec-edgar","filing":"0001415889-25-011874","document":"form4-05022025_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011874/form4-05022025_080503.xml","form_type":"4"}},{"id":1167134,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-24T00:00:05.000Z","date":"2025-04-21","kind":"exercise","planned":true,"acquired":false,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":90665,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001415889-25-011243","document":"form4-04232025_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011243/form4-04232025_080401.xml","form_type":"4"}},{"id":1167133,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-04-24T00:00:05.000Z","date":"2025-04-21","kind":"sale","planned":true,"acquired":false,"shares":3334,"price":30,"value":100020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."}],"balance_after":82139,"source":{"system":"sec-edgar","filing":"0001415889-25-011243","document":"form4-04232025_080401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011243/form4-04232025_080401.xml","form_type":"4"}},{"id":1167132,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-04-24T00:00:05.000Z","date":"2025-04-21","kind":"exercise","planned":true,"acquired":true,"shares":3334,"price":4.21,"value":14036.14,"ownership":{"direct":true},"balance_after":85473,"source":{"system":"sec-edgar","filing":"0001415889-25-011243","document":"form4-04232025_080401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925011243/form4-04232025_080401.xml","form_type":"4"}},{"id":1217562,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T23:05:32.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":110206,"price":31.02,"value":3418590.12,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.74 to $31.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."}],"balance_after":10141287,"source":{"system":"sec-edgar","filing":"0001415889-25-007443","document":"form4-03072025_110328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925007443/form4-03072025_110328.xml","form_type":"4"}},{"id":1217561,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T23:05:32.000Z","date":"2025-03-06","kind":"purchase","planned":false,"acquired":true,"shares":372093,"price":30.78,"value":11453022.54,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 to $31.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."}],"balance_after":10031081,"source":{"system":"sec-edgar","filing":"0001415889-25-007443","document":"form4-03072025_110328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925007443/form4-03072025_110328.xml","form_type":"4"}},{"id":1217560,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T23:05:32.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":37455,"price":31.3,"value":1172341.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.90 to $31.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."}],"balance_after":9658988,"source":{"system":"sec-edgar","filing":"0001415889-25-007443","document":"form4-03072025_110328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925007443/form4-03072025_110328.xml","form_type":"4"}},{"id":1217559,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T23:05:32.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":304287,"price":30.56,"value":9299010.72,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.90 to $30.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."}],"balance_after":9621533,"source":{"system":"sec-edgar","filing":"0001415889-25-007443","document":"form4-03072025_110328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925007443/form4-03072025_110328.xml","form_type":"4"}},{"id":1222964,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-06T01:00:13.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":false,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":93999,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001415889-25-007104","document":"form4-03052025_080309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925007104/form4-03052025_080309.xml","form_type":"4"}},{"id":1222963,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-03-06T01:00:13.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":901,"price":32.8509,"value":29598.6609,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $32.8509 and the range of prices were between $32.53 and $33.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":82139,"source":{"system":"sec-edgar","filing":"0001415889-25-007104","document":"form4-03052025_080309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925007104/form4-03052025_080309.xml","form_type":"4"}},{"id":1222962,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-03-06T01:00:13.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":2433,"price":31.8848,"value":77575.7184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $31.8848 and the range of prices were between $31.50 and $32.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":83040,"source":{"system":"sec-edgar","filing":"0001415889-25-007104","document":"form4-03052025_080309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925007104/form4-03052025_080309.xml","form_type":"4"}},{"id":1222961,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-03-06T01:00:13.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":true,"shares":3334,"price":4.21,"value":14036.14,"ownership":{"direct":true},"balance_after":85473,"source":{"system":"sec-edgar","filing":"0001415889-25-007104","document":"form4-03052025_080309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925007104/form4-03052025_080309.xml","form_type":"4"}},{"id":1282137,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-06T01:00:05.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":false,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":97333,"derivative":{"exercise_price":4.21,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001415889-25-003165","document":"form4-02052025_080201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925003165/form4-02052025_080201.xml","form_type":"4"}},{"id":1282136,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-06T01:00:05.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":100,"price":43.6,"value":4360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."}],"balance_after":82139,"source":{"system":"sec-edgar","filing":"0001415889-25-003165","document":"form4-02052025_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925003165/form4-02052025_080201.xml","form_type":"4"}},{"id":1282135,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-06T01:00:05.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":816,"price":42.7703,"value":34900.5648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $42.7703 and the range of prices were between $42.56 and $43.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":82239,"source":{"system":"sec-edgar","filing":"0001415889-25-003165","document":"form4-02052025_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925003165/form4-02052025_080201.xml","form_type":"4"}},{"id":1282134,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-06T01:00:05.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":2418,"price":42.0756,"value":101738.8008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $42.0756 and the range of prices were between $41.55 and $42.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":83055,"source":{"system":"sec-edgar","filing":"0001415889-25-003165","document":"form4-02052025_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925003165/form4-02052025_080201.xml","form_type":"4"}},{"id":1282133,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-06T01:00:05.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":true,"shares":3334,"price":4.21,"value":14036.14,"ownership":{"direct":true},"balance_after":85473,"source":{"system":"sec-edgar","filing":"0001415889-25-003165","document":"form4-02052025_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925003165/form4-02052025_080201.xml","form_type":"4"}},{"id":1306832,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-09T01:00:05.000Z","date":"2025-01-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":60.0008,"value":300004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $60.0008 and the range of prices were between $60.00 and $60.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":293054,"source":{"system":"sec-edgar","filing":"0001415889-25-001165","document":"form4-01082025_080101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588925001165/form4-01082025_080101.xml","form_type":"4"}},{"id":1315115,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70598,"kind":"person","name":"Winter Charles M.","position":1,"cik":"0001960264","reported_name":"Winter Charles M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-04T01:10:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":80500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":80500,"derivative":{"exercise_price":53.24,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":80500},"source":{"system":"sec-edgar","filing":"0001415889-25-000676","document":"form4-01032025_080109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925000676/form4-01032025_080109.xml","form_type":"4"}},{"id":1315114,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70598,"kind":"person","name":"Winter Charles M.","position":1,"cik":"0001960264","reported_name":"Winter Charles M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-04T01:10:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,297 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the \"Plan\") on November 15, 2021, 1,644 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023, 2,834 shares acquired under the Plan on May 15, 2024 and 1 share acquired under the Plan on November 15, 2024."}],"balance_after":77288,"source":{"system":"sec-edgar","filing":"0001415889-25-000676","document":"form4-01032025_080109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588925000676/form4-01032025_080109.xml","form_type":"4"}},{"id":1315208,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-01-04T01:10:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":283500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":283500,"derivative":{"exercise_price":53.24,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":283500},"source":{"system":"sec-edgar","filing":"0001415889-25-000675","document":"form4-01032025_080107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588925000675/form4-01032025_080107.xml","form_type":"4"}},{"id":1315207,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":27516,"kind":"person","name":"Campbell David Alan","position":1,"cik":"0001864158","reported_name":"Campbell David Alan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-04T01:10:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026."}],"balance_after":298054,"source":{"system":"sec-edgar","filing":"0001415889-25-000675","document":"form4-01032025_080107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864158/000141588925000675/form4-01032025_080107.xml","form_type":"4"}},{"id":1315644,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":47724,"kind":"person","name":"Dobek Maria","position":1,"cik":"0002032671","reported_name":"Dobek Maria","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Accounting"}}],"security":"Stock option (right to buy)","published_at":"2025-01-04T01:10:04.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":31500,"derivative":{"exercise_price":53.24,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001415889-25-000672","document":"form4-01032025_080101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2032671/000141588925000672/form4-01032025_080101.xml","form_type":"4"}},{"id":1315643,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":47724,"kind":"person","name":"Dobek Maria","position":1,"cik":"0002032671","reported_name":"Dobek Maria","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Accounting"}}],"security":"Common Stock","published_at":"2025-01-04T01:10:04.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the \"Plan\") on November 15, 2024."}],"balance_after":14001,"source":{"system":"sec-edgar","filing":"0001415889-25-000672","document":"form4-01032025_080101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032671/000141588925000672/form4-01032025_080101.xml","form_type":"4"}},{"id":1315216,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T22:10:04.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":63000,"derivative":{"exercise_price":53.24,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001415889-25-000554","document":"form4-01032025_050101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925000554/form4-01032025_050101.xml","form_type":"4"}},{"id":1315215,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70603,"kind":"person","name":"Meyer Andrew Hollman","position":1,"cik":"0001864159","reported_name":"Meyer Andrew Hollman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:10:04.000Z","date":"2025-01-02","kind":"sale","planned":false,"acquired":false,"shares":200,"price":57.365,"value":11473.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $57.365 and the range of prices were between $57.35 and $57.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":82139,"source":{"system":"sec-edgar","filing":"0001415889-25-000554","document":"form4-01032025_050101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864159/000141588925000554/form4-01032025_050101.xml","form_type":"4"}}],"next_cursor":"2025-01-03T22:10:04.000000Z,1315215"}